论文部分内容阅读
目的通过检测不同病程的糖尿病(DM)患者胱蛋白酶抑制剂C(CystC)含量,同时与血清尿素氮(BUN)、血肌酐(SCr)、尿酸(UA)、β2-微球蛋白(β2-MG)、及尿白蛋白(Alb)含量比较,探讨CystC在糖尿病肾病(DN)早期诊断中的价值。方法对不同病程阶段121例糖尿病患者,同时测定尿中白蛋白及血清CystC、BUN、SCr、UA、β2-MG含量并与尿白蛋白进行相关性分析及显著性检验。结果121例不同病程阶段糖尿病患者血清γ痕迹蛋白、β2-MG、BUN、SCr与尿白蛋白相关性分别为0.954、0.91、0.684、0.63呈显著相关。糖尿病病程<5年、6~9年、≥10年3组患者的BUN、SCr、UA、β2-MG、、CystC、尿白蛋白6个指标分别进行比较,差异均有统计学意义(P<0.01)。结论CystC是一较理想的反映肾功能的血清标志物,建议在常规检测BUN、SCr、UA、β2-MG及尿白蛋白含量的基础上,联合应用CystC可更早地发现糖尿病肾病。
Objective To detect cystatin C (CystC) in patients with diabetes mellitus (DM) at different stages of diabetes mellitus, and to evaluate the relationship between serum cystatin C (BUN), serum creatinine (SCr), uric acid (UA), β2-microglobulin ), And urinary albumin (Alb) in order to investigate the value of CystC in the early diagnosis of diabetic nephropathy (DN). Methods The serum levels of albumin and serum CystC, BUN, SCr, UA and β2-MG were measured in 121 patients with different stages of diabetes mellitus and their correlations with urinary albumin and their significance were tested. Results The serum levels of γ-trace protein, β2-MG, BUN, SCr and urinary albumin in 121 patients with different stages of diabetes were 0.954,0.91,0.684,0.63 respectively. Six indicators of BUN, SCr, UA, β2-MG, CystC and urinary albumin in patients with diabetes mellitus <5 years, 6 to 9 years and ≥10 years were compared respectively and the differences were statistically significant (P < 0.01). Conclusions CystC is an ideal serum marker to reflect renal function. It is suggested that combined use of CystC can detect diabetic nephropathy earlier than conventional detection of BUN, SCr, UA, β2-MG and urinary albumin.